Patents by Inventor Wilson Edwards

Wilson Edwards has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GLUCAGON LIKE PEPTIDE 1 (GLP-1) FUSION PEPTIDE COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE CONJUGATES AND USES THEREOF
    Publication number: 20240117000
    Abstract: The present invention comprises conjugates comprising a glucagon-like peptide 1 (GLP-1) fusion peptide coupled to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.
    Type: Application
    Filed: August 31, 2023
    Publication date: April 11, 2024
    Inventors: Yue-Mei ZHANG, Raul CAMACHO, Martin A. CASE, Ellen CHI, Suzanne EDAVETTAL, Wilson EDWARDS, Lisa NORQUAY, Mark J. WALL, Rui ZHANG, Songmao ZHENG
  • ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS
    Publication number: 20230365644
    Abstract: The present invention comprises conjugates comprising a monoclonal antibody conjugated to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.
    Type: Application
    Filed: January 12, 2023
    Publication date: November 16, 2023
    Inventors: Mark MACIELAG, Raymond J. PATCH, Rui ZHANG, Martin A. CASE, Shamina M. RANGWALA, James N. LEONARD, Raul C. CAMACHO, Michael J. HUNTER, Katharine E. D'AQUINO, Wilson EDWARDS, Ronald V. SWANSON, Wenying JIAN, Yue-Mei ZHANG, Mark WALL, Ellen CHI
  • Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
    Patent number: 11780900
    Abstract: The present invention comprises conjugates comprising a glucagon-like peptide 1 (GLP-1) fusion peptide coupled to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: October 10, 2023
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: Yue-Mei Zhang, Raul Camacho, Martin A. Case, Ellen Chi, Suzanne Edavettal, Wilson Edwards, Lisa Norquay, Mark J. Wall, Rui Zhang, Songmao Zheng
  • Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors
    Patent number: 11767354
    Abstract: The present invention comprises conjugates comprising a monoclonal antibody conjugated to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.
    Type: Grant
    Filed: February 5, 2021
    Date of Patent: September 26, 2023
    Assignee: Janssen Pharmaceutica NV
    Inventors: Mark Macielag, Raymond J. Patch, Rui Zhang, Martin A. Case, Shamina M. Rangwala, James N. Leonard, Raul C. Camacho, Michael J. Hunter, Katharine E. D'Aquino, Wilson Edwards, Ronald V. Swanson, Wenying Jian, Yue-Mei Zhang, Mark J. Wall, Ellen Chi
  • Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors
    Patent number: 11591379
    Abstract: The present invention comprises conjugates comprising a monoclonal antibody conjugated to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.
    Type: Grant
    Filed: March 16, 2020
    Date of Patent: February 28, 2023
    Assignee: Janssen Pharmaceutica NV
    Inventors: Mark Macielag, Raymond J. Patch, Rui Zhang, Martin A. Case, Shamina M. Rangwala, James N. Leonard, Raul C. Camacho, Michael J. Hunter, Katharine E. D'Aquino, Wilson Edwards, Ronald V. Swanson, Wenying Jian, Yue-Mei Zhang, Mark J. Wall, Ellen Chi
  • IMMUNOPET AND IMMUNOSPECT IMAGING TO IDENTIFY CYTOTOXIC T CELL ACTIVITY
    Publication number: 20220296737
    Abstract: Provided herein is a method for identifying cytotoxic T cell activity due to cancer immunotherapy in a subject. In some embodiments, the method comprises administering an effective amount of a tracer for positron emission tomography (PET) or single photon emission computed tomography (SPECT) to a subject receiving a cancer immunotherapy, wherein the tracer comprises an antibody or antigen-binding fragment thereof that specifically binds to a luminal domain of a lymphocytic granule-associated molecule (LGAM) labeled with a PET or SPECT detectable moiety, and detecting the signal of the tracer by PET or SPECT imaging to identify the cytotoxic T cell activity due to immune therapy for the cancer in the subject. In several embodiments, the antibody or antigen binding fragment specifically binds to the luminal domain of CD107a.
    Type: Application
    Filed: March 3, 2022
    Publication date: September 22, 2022
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Carolyn Anderson, Wilson Edwards, Gary Kohanbash
  • Immunoglobulins and uses thereof
    Patent number: 11401315
    Abstract: The present invention relates to a monoclonal antibody platform designed to be coupled to therapeutic peptides to increase the half-life of the therapeutic peptide in a subject. The invention also relates to pharmaceutical compositions and methods for use thereof.
    Type: Grant
    Filed: August 21, 2020
    Date of Patent: August 2, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: Mark Macielag, Raymond J. Patch, Rui Zhang, Martin A. Case, Shamina M. Rangwala, James N. Leonard, Raul C. Camacho, Michael J. Hunter, Katharine E. D'Aquino, Wilson Edwards, Ronald V. Swanson, Wenying Jian, Yue-Mei Zhang, Mark J. Wall, Ellen Chi
  • Antibodies to Pyroglutamate Amyloid-B and Uses Thereof
    Publication number: 20220177560
    Abstract: The invention provides antibodies or antigen binding fragments thereof that bind to 3pE A? and methods of making and using the antibodies or antigen binding fragments thereof, including use for formulations, administration and kits. The antibody and antigen binding fragments thereof and methods disclosed are useful for diagnosis, prognosis and treatment of Alzheimer's disease or other ?-amyloid-related diseases.
    Type: Application
    Filed: March 25, 2020
    Publication date: June 9, 2022
    Inventors: Bianca Van Broeck, Marc Mercken, Wilson Edwards, Sanjaya Singh, Jinquan Luo, Sherry La Porte, Rajkumar Ganesan, Chichi Huang
  • ANTIBODIES TO PYROGLUTAMATE AMYLOID-B AND USES THEREOF
    Publication number: 20220106387
    Abstract: The invention provides antibodies or antigen binding fragments thereof that bind to 3pE A? and methods of making and using the antibodies or antigen binding fragments thereof, including use for formulations, administration and kits. The antibody and antigen binding fragments thereof and methods disclosed are useful for diagnosis, prognosis and treatment of Alzheimer's disease or other ?-amyloid-related diseases.
    Type: Application
    Filed: December 17, 2021
    Publication date: April 7, 2022
    Inventors: Bianca Van Broeck, Marc Mercken, Wilson Edwards, Sanjaya Singh, Jinquan Luo, Sherry La Porte, Rajkumar Ganesan, Chichi Huang
  • ANTI-IDIOTYPIC ANTIBODIES AGAINST ANTI-GPRC5D ANTIBODIES
    Publication number: 20220064284
    Abstract: In certain aspects, the disclosure relates to anti-idiotype antibodies and antigen-binding portions thereof that specifically bind a GP5B83 containing protein, e.g., an antibody or antigen-binding portions thereof. In some aspects, the anti-idiotype antibodies and antigen-binding portions of the present disclosure can be used in methods to detect and quantify cells expressing chimeric antigen receptors that include GP5B83.
    Type: Application
    Filed: July 15, 2021
    Publication date: March 3, 2022
    Inventors: Ellen CHI, Wilson EDWARDS, Matt HUSOVSKY, Ann LACOMBE, Christian MARTINEZ, H. Mimi ZHOU, John T. LEE
  • ANTI-IDIOTYPIC ANTIBODIES AGAINST ANTI-KLK2 ANTIBODIES
    Publication number: 20220064334
    Abstract: In certain aspects, the disclosure relates to anti-idiotype antibodies and antigen-binding portions thereof that specifically bind a KL2B413 containing protein, e.g., an antibody or antigen-binding portions thereof. In some aspects, the anti-idiotype antibodies and antigen-binding portions of the present disclosure can be used in methods to detect and quantify cells expressing chimeric antigen receptors that include KL2B413.
    Type: Application
    Filed: July 15, 2021
    Publication date: March 3, 2022
    Inventors: Zemeda AINEKULU, Qiang CHEN, Ellen CHI, Wilson EDWARDS, Matt HUSOVSKY, Ann LACOMBE, Quynh NGUYEN, Paul H. KIM, H. Mimi ZHOU, John T. LEE
  • Antibodies to pyroglutamate amyloid-? and uses thereof
    Patent number: 11236155
    Abstract: The invention provides antibodies or antigen binding fragments thereof that bind to 3pE A? and methods of making and using the antibodies or antigen binding fragments thereof, including use for formulations, administration and kits. The antibody and antigen binding fragments thereof and methods disclosed are useful for diagnosis, prognosis and treatment of Alzheimer's disease or other ?-amyloid-related diseases.
    Type: Grant
    Filed: March 25, 2020
    Date of Patent: February 1, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: Bianca Van Broeck, Marc Mercken, Wilson Edwards, Sanjaya Singh, Jinquan Luo, Sherry La Porte, Rajkumar Ganesan, Chichi Huang
  • GLUCAGON LIKE PEPTIDE 1 (GLP-1) FUSION PEPTIDE COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE CONJUGATES AND USES THEREOF
    Publication number: 20210253661
    Abstract: The present invention comprises conjugates comprising a glucagon-like peptide 1 (GLP-1) fusion peptide coupled to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.
    Type: Application
    Filed: April 24, 2019
    Publication date: August 19, 2021
    Inventors: Yue-Mei ZHANG, Raul CAMACHO, Martin A. CASE, Ellen CHI, Suzanne EDAVETTAL, Wilson EDWARDS, Lisa NORQUAY, Mark J. WALL, Rui ZHANG, Songmao ZHENG
  • Antibody-Coupled Cyclic Peptide Tyrosine Tyrosine Compounds as Modulators of Neuropeptide Y Receptors
    Publication number: 20210163566
    Abstract: The present invention comprises conjugates comprising a monoclonal antibody conjugated to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.
    Type: Application
    Filed: February 5, 2021
    Publication date: June 3, 2021
    Inventors: Mark MACIELAG, Raymond J. PATCH, Rui ZHANG, Martin A. CASE, Shamina M. RANGWALA, James N. LEONARD, Raul C. CAMACHO, Michael J. HUNTER, Katharine E. D'AQUINO, Wilson EDWARDS, Ronald V. SWANSON, Wenying JIAN, Yue-Mei ZHANG, Mark J. WALL, Ellen CHI
  • Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors
    Patent number: 10968265
    Abstract: The present invention comprises conjugates comprising a monoclonal antibody conjugated to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: April 6, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Mark Macielag, Raymond J. Patch, Rui Zhang, Martin A. Case, Shamina M. Rangwala, James N. Leonard, Raul C. Camacho, Michael J. Hunter, Katharine E. D'Aquino, Wilson Edwards, Ronald V. Swanson, Wenying Jian, Yue-Mei Zhang, Mark J. Wall, Ellen Chi
  • IMMUNOGLOBULINS AND USES THEREOF
    Publication number: 20210094998
    Abstract: The present invention relates to a monoclonal antibody platform designed to be coupled to therapeutic peptides to increase the half-life of the therapeutic peptide in a subject. The invention also relates to pharmaceutical compositions and methods for use thereof.
    Type: Application
    Filed: October 30, 2020
    Publication date: April 1, 2021
    Inventors: Mark MACIELAG, Raymond J. PATCH, Rui ZHANG, Martin A. CASE, Mark J. WALL, Yue-Mei ZHANG, Shamina M. RANGWALA, James N. LEONARD, Raul C. CAMACHO, Michael J. HUNTER, Katharine E. D'AQUINO, Wilson EDWARDS, Ronald V. SWANSON, Wenying JIAN, Ellen CHI
  • Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
    Patent number: 10875902
    Abstract: The present invention comprises conjugates comprising a glucagon-like peptide 1 (GLP-1) fusion peptide coupled to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: December 29, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Yue-Mei Zhang, Raul C. Camacho, Martin A. Case, Ellen Chi, Suzanne Edavettal, Wilson Edwards, Lisa Norquay, Mark J. Wall, Rui Zhang, Songmao Zheng
  • IMMUNOGLOBULINS AND USES THEREOF
    Publication number: 20200385439
    Abstract: The present invention relates to a monoclonal antibody platform designed to be coupled to therapeutic peptides to increase the half-life of the therapeutic peptide in a subject. The invention also relates to pharmaceutical compositions and methods for use thereof.
    Type: Application
    Filed: August 21, 2020
    Publication date: December 10, 2020
    Inventors: Mark MACIELAG, Raymond J. Patch, Rui Zhang, Martin A. Case, Shamina M. Rangwala, James N. Leonard, Raul C. Camacho, Michael J. Hunter, Katharine E. D'Aquino, Wilson Edwards, Ronald V. Swanson, Wenying Jian, Yue-Mei Zhang, Mark J. Wall, Ellen Chi
  • Immunoglobulins and uses thereof
    Patent number: 10858413
    Abstract: The present invention relates to a monoclonal antibody platform designed to be coupled to therapeutic peptides to increase the half-life of the therapeutic peptide in a subject. The invention also relates to pharmaceutical compositions and methods for use thereof.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: December 8, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Mark Macielag, Raymond J. Patch, Rui Zhang, Martin A. Case, Mark J. Wall, Yue-Mei Zhang, Shamina M. Rangwala, James N. Leonard, Raul C. Camacho, Michael J. Hunter, Katharine E. D'Aquino, Wilson Edwards, Ronald V. Swanson, Wenying Jian, Ellen Chi
  • Antibodies to Pyroglutamate Amyloid-B and Uses Thereof
    Publication number: 20200308261
    Abstract: The invention provides antibodies or antigen binding fragments thereof that bind to 3pE A? and methods of making and using the antibodies or antigen binding fragments thereof, including use for formulations, administration and kits. The antibody and antigen binding fragments thereof and methods disclosed are useful for diagnosis, prognosis and treatment of Alzheimer's disease or other ?-amyloid-related diseases.
    Type: Application
    Filed: March 25, 2020
    Publication date: October 1, 2020
    Inventors: Bianca Van Broeck, Marc Mercken, Wilson Edwards, Sanjaya Singh, Jinquan Luo, Sherry La Porte, Rajkumar Ganesan, Chichi Huang